再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

休市中 04-04 16:00:00 EDT

31.77

-4.92

-13.41%

盘后31.77

+0.000.00%

19:55 EDT

最高34.98	最低31.28	成交量175.44万
今开34.33	昨收36.69	日振幅10.08%
总市值34.67亿	流通市值31.71亿	总股本1.09亿
成交额5,645万	换手率1.76%	流通股本9,981万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":31.77,"timestamp":1743796800000,"preClose":36.69,"halted":0,"volume":1754398,"hourTrading":{"tag":"盘后","latestPrice":31.77,"preClose":31.77,"latestTime":"19:55 EDT","volume":1898,"amount":60307.95,"timestamp":1743810953169},"delay":0,"floatShares":99806342,"shares":109137154,"eps":-2.59837,"marketStatus":"休市中","change":-4.92,"latestTime":"04-04 16:00:00 EDT","open":34.33,"high":34.98,"low":31.28,"amount":56452185.50495,"amplitude":0.100845,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.59837,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":36.69,"preHourTrading":{"tag":"盘前","latestPrice":33.5,"preClose":36.69,"latestTime":"09:25 EDT","volume":5390,"amount":186111.28844,"timestamp":1743773153389},"postHourTrading":{"tag":"盘后","latestPrice":31.77,"preClose":31.77,"latestTime":"19:55 EDT","volume":1898,"amount":60307.95,"timestamp":1743810953169},"volumeRatio":1.1085880412184215,"impliedVol":0.7543,"impliedVolPercentile":0.6175},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2518220774","title":"再鼎医药盘中异动 早盘股价大跌5.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220774","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518220774?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:01","pubTimestamp":1741615262,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时01分，再鼎医药股票出现波动，股价急速跳水5.35%。截至发稿，该股报34.47美元/股，成交量11.2824万股，换手率0.10%，振幅4.68%。再鼎医药股票所在的生物技术行业中，整体涨幅为0.12%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3092.10%、664.70%、298.02%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Impact Biomedical, Inc.，振幅分别为41.36%、40.24%、28.59%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220102a26a3005&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310220102a26a3005&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZLAB","BK4548","BK4526","BK4588","BK4585","BK4531"],"gpt_icon":0},{"id":"2517035469","title":"再鼎医药(ZLAB.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价55.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517035469","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517035469?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:13","pubTimestamp":1741385596,"startTime":"0","endTime":"0","summary":"再鼎医药(ZLAB.US)获Scotiabank首次覆盖，给予跑赢大盘评级, 目标价55.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08061348605305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ZLAB","09688"],"gpt_icon":0},{"id":"2517431171","title":"再鼎医药上涨5.31%，报37.27美元/股，总市值40.86亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517431171","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517431171?lang=zh_cn&edition=full","pubTime":"2025-03-07 22:55","pubTimestamp":1741359317,"startTime":"0","endTime":"0","summary":"3月7日，再鼎医药盘中上涨5.31%，截至22:55，报37.27美元/股，成交551.06万美元，总市值40.86亿美元。财务数据显示，截至2024年12月31日，再鼎医药收入总额3.99亿美元，同比增长49.59%；归母净利润-2.57亿美元，同比增长23.17%。大事提醒：3月3日，再鼎医药获美国银行重申评级Neutral，目标价上调至36.1美元。再鼎医药的长期目标是成为全球领先的生物制药公司,以中国为基,为全球患者提供创新疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/07225548603508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","BK4526","ZLAB","BK4588","BK1161","BK4548","BK1574","LU2488822045.USD","BK4585","BK4531","BK1588","09688"],"gpt_icon":0},{"id":"2517620291","title":"再鼎医药2024财年实现净利润-2.57亿美元，同比增加23.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517620291","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517620291?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:00","pubTimestamp":1741276852,"startTime":"0","endTime":"0","summary":"3月7日，再鼎医药公布财报，公告显示公司2024财年净利润为-2.57亿美元，同比增加23.28%；其中营业收入为3.99亿美元，同比增加49.44%，每股基本收益为-2.60美元。从资产负债表来看，再鼎医药总负债3.45亿美元，其中短期债务1.40亿美元，资产负债比为3.44，流动比率为3.52。机构评级：截至2025年3月7日，当前有11家机构对再鼎医药目标价做出预测，其中目标均价为51.64美元，其中最低目标价为36.03美元，最高目标价为74.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000103abeb8cee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000103abeb8cee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB"],"gpt_icon":0},{"id":"2517838134","title":"再鼎医药(09688)根据2024年股权激励计划授出可认购合共4700股美国存托股份的购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2517838134","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517838134?lang=zh_cn&edition=full","pubTime":"2025-03-06 17:30","pubTimestamp":1741253414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2025年3月3日(美国东部时间)，公司根据2024年股权激励计划向3名承授人授出可认购合共4700股美国存托股份的购股权并向9名承授人涉及合共1.01万股美国存托股份的受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","ZLAB","BK1588","BK4526","BK1161","BK4585","BK4588","BK4548","BK1574","09688","BK4139","BK4531"],"gpt_icon":0},{"id":"2517135516","title":"财报发布后获多家投行一致看多 商业化加速兑现驱动再鼎医药价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2517135516","media":"格隆汇","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517135516?lang=zh_cn&edition=full","pubTime":"2025-03-06 16:46","pubTimestamp":1741250793,"startTime":"0","endTime":"0","summary":"在业绩披露窗口期，创新药企的成长韧性正在接受市场检验。财报发布后也引起了国内外多家投行的关注和分析。多家机构普遍认为，以再鼎医药为代表的中国创新药企或已进入商业化能力验证与管线价值释放的双击周期。针对其后续的市场表现，多家投行持续表达了积极乐观的预期，并上调目标价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306164648963bee52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306164648963bee52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"财报发布后获多家投行一致看多 商业化加速兑现驱动再鼎医药价值重估","news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"1190164244","title":"异动解读 | 再鼎医药盘中大涨5.88% 高盛看好公司未来发展","url":"https://stock-news.laohu8.com/highlight/detail?id=1190164244","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190164244?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:12","pubTimestamp":1741187540,"startTime":"0","endTime":"0","summary":"再鼎医药(ZLAB)今日盘中大涨5.88%,引发市场关注。\n\n消息面上,高盛发表研究报告看好再鼎医药2025年的发展前景。报告指出,再鼎医药2024年第四季度收入同比增长66%,符合预期,各产品销售情况良好。高盛预计,2025年将是再鼎医药的重要里程碑年,预计下半年实现整体盈利。\n\n高盛重点关注再鼎医药多款在研新药的进展,包括bemarituzumab在卵巢癌领域的新适应症申请、TIVDAK用于治疗三阴性乳腺癌的上市申请进展,以及肿瘤电场治疗仪Optune的新适应症申请等。高盛由于看好公司未来发展前景,给予再鼎医药\"买入\"评级,并上调股价目标价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 再鼎医药盘中大涨5.88% 高盛看好公司未来发展","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"gpt_icon":0},{"id":"2517943424","title":"再鼎医药盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943424","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517943424?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:00","pubTimestamp":1741186809,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时00分，再鼎医药股票出现波动，股价急速拉升5.00%。再鼎医药股票所在的生物技术行业中，整体涨幅为1.27%。】高盛发表研究报告指出，再鼎医药 2024 年第四季收入按年增长 66%至 1.085 亿美元，符合该行预期的 1.08 亿美元，各项产品收入表现均符合预测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305230009989d4c9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305230009989d4c9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4531","BK4526","BK4585","BK4139","ZLAB","BK4548"],"gpt_icon":0},{"id":"2517934330","title":"港股异动 | 再鼎医药(09688)涨超7% 绩后获多家大行调升目标价 公司今年催化剂丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2517934330","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517934330?lang=zh_cn&edition=full","pubTime":"2025-03-05 09:35","pubTimestamp":1741138507,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超7%，截至发稿，涨7.86%，报27.45港元，成交额3074.33万港元。消息面上，再鼎医药此前发布截至2024年12月31日止年度业绩，总收入为3.990亿美元，同比增长50%；2025年全年收入指引为5.60亿美元至5.90亿美元。高盛将公司H股目标价从40.4港元上调至42.01港元，重申2025年是再鼎医药发展里程碑年。中金表示，维持再鼎医药“跑赢大市”评级，将港股目标价上调22.5%至34.41港元。至于KarXT，该行预计在明年开始商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ZLAB","09688"],"gpt_icon":0},{"id":"1177548190","title":"再鼎医药逆市上涨，新药获批在中国台湾地区上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1177548190","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177548190?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:28","pubTimestamp":1741102096,"startTime":"0","endTime":"0","summary":"进一步丰富了临床治疗手段。","market":"us","thumbnail":"https://static.tigerbbs.com/cb5b39366258c0a0832a4d774c91bde9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/cb5b39366258c0a0832a4d774c91bde9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1257755.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ZLAB"],"gpt_icon":0},{"id":"2516608421","title":"美股异动 | 再鼎医药(ZLAB.US)涨逾5% 新药repotrectinib获批在台湾地区上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2516608421","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516608421?lang=zh_cn&edition=full","pubTime":"2025-03-04 23:19","pubTimestamp":1741101578,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周二，再鼎医药(ZLAB.US)涨逾5%，报33.53美元。消息面上，再鼎医药近日宣布，中国台湾地区药品审评机构已批准其新药repotrectinib的新药上市申请。该药物主要用于治疗ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者，以及NTRK基因融合阳性的实体肿瘤成人患者。这款创新药物在中国大陆的注册商品名为奥凯乐，此次获批标志着再鼎医药在拓展市场、惠及更多患者方面迈出了重要一步。repotrectinib的上市将为相关癌症患者提供新的治疗选择，进一步丰富了临床治疗手段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"美股异动 | 再鼎医药(ZLAB.US)涨逾5% 新药repotrectinib获批在台湾地区上市","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4585","BK4531","BK4588","BK1588","BK4526","BK1161","BK1574","09688","LU2488822045.USD","ZLAB","BK4548"],"gpt_icon":0},{"id":"1168191430","title":"异动解读 | 花旗高盛看好未来两年催化剂 再鼎医药盘中大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168191430","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168191430?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:40","pubTimestamp":1741099241,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大涨5%,主要受多家投行看好该股未来发展前景所推动。中金发布研报称,维持再鼎医药\"跑赢大市\"评级,并将目标价上调22.5%至34.41港元。花旗将再鼎医药目标价轻微上调至71美元,给予\"买入\"评级。该行认为,今年渠道数据、Vygart的增长,以及2026年KarXT获准上市的前景,将重新激发投资者对该股的热情。高盛也将再鼎医药目标价上调至42.01港元,重申2025年是该公司的发展里程碑年。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"gpt_icon":0},{"id":"2516775746","title":"再鼎医药盘中异动 快速拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516775746","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516775746?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:39","pubTimestamp":1741099157,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时39分，再鼎医药股票出现异动，股价大幅上涨5.04%。再鼎医药股票所在的生物技术行业中，整体涨幅为0.12%。】高盛发表研究报告指出，再鼎医药 2024 年第四季收入按年增长 66%至 1.085 亿美元，符合该行预期的 1.08 亿美元，各项产品收入表现均符合预测。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223917989bae72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223917989bae72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","ZLAB","BK4526","BK4139","BK4585","BK4531","BK4588"],"gpt_icon":0},{"id":"2516562822","title":"美股异动｜再鼎医药盘前涨超3% 绩后获多家大行上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2516562822","media":"港股那点事","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516562822?lang=zh_cn&edition=full","pubTime":"2025-03-04 17:15","pubTimestamp":1741079700,"startTime":"0","endTime":"0","summary":"格隆汇3月4日｜再鼎医药盘前涨超3%，报32.7美元。花旗将再鼎医药美股目标价由70美元轻微上调至71美元，给予“买入”评级，相信今年的渠道数据、Vygart增长、越来越接近2026年KarXT推出的前景，应能重新激发投资者对该股的情绪。高盛将再鼎医药H股目标价从40.4港元上调至42.01港元，给予“买入”评级，重申2025年是再鼎医药发展里程碑年。中金将再鼎医药H股目标价上调22.5%至34.41港元，维持“跑赢大市”评级，留意到公司在今明两年有大量的催化剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-03-04/doc-inennutp2725362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ZLAB","09688"],"gpt_icon":0},{"id":"2516949645","title":"【中金升再鼎医药目标价至34.41港元】中金升再鼎医药目标价至34.41港元，今年指引反映增长较高。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516949645","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516949645?lang=zh_cn&edition=full","pubTime":"2025-03-04 15:26","pubTimestamp":1741073216,"startTime":"0","endTime":"0","summary":"中金升再鼎医药目标价至34.41港元，今年指引反映增长较高。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04152648506190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ZLAB","09688"],"gpt_icon":0},{"id":"2516164536","title":"中金升再鼎医药目标价至34.41港元 今年指引反映增长较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2516164536","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516164536?lang=zh_cn&edition=full","pubTime":"2025-03-04 15:25","pubTimestamp":1741073127,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1161","BK4585","BK1588","BK4588","HSCEI","09688","BK4531","BK4548","BK4526","ZLAB","BK4139","HSTECH","LU2488822045.USD","YANG","BK1574","07226"],"gpt_icon":0},{"id":"2516645574","title":"中金：维持再鼎医药(09688)“跑赢大市”评级 升目标价至34.41港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516645574","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516645574?lang=zh_cn&edition=full","pubTime":"2025-03-04 15:10","pubTimestamp":1741072232,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持再鼎医药(09688)“跑赢大市”评级，将港股目标价上调22.5%至34.41港元。再鼎医药去年业绩稍微胜过该行预期，主要得益于艾加莫德(Efgartigimod)收入高企。公司为今年表现提供指引，收入达5.6亿美元至5.9亿美元，目标非通用会计准则经营盈利在今年第四季收支平衡，超该行预期。中金指，留意到公司在今明两年有大量的催化剂，料今年上半年会就ZL-1310公布更多数据，另预期会在上半年就Bemarituzumab递交内地上市申请。至于KarXT，该行料在明年开始商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"2516351645","title":"研报掘金｜中金：上调再鼎医药H股目标价至34.41港元 指今明两年有大量催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2516351645","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516351645?lang=zh_cn&edition=full","pubTime":"2025-03-04 15:07","pubTimestamp":1741072026,"startTime":"0","endTime":"0","summary":"中金发表研究报告指，再鼎医药去年业绩稍微胜过该行预期，主要得益于艾加莫德收入高企。公司为今年表现提供指引，收入达5.6亿美元至5.9亿美元，目标非通用会计准则经营盈利在今年第四季收支平衡，超该行预期。中金指，留意到公司在今明两年有大量的催化剂，料今年上半年会就ZL-1310公布更多数据，另预期会在上半年就Bemarituzumab递交内地上市申请。至于KarXT，该行料在明年开始商业化。该行上调再鼎医药H股目标价22.5%至34.41港元，维持“跑赢大市”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503041511459638ba56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503041511459638ba56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB"],"gpt_icon":0},{"id":"2516648844","title":"研报掘金｜中金：上调再鼎医药H股目标价至34.41港元 指今明两年有大量催化剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2516648844","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516648844?lang=zh_cn&edition=full","pubTime":"2025-03-04 14:49","pubTimestamp":1741070982,"startTime":"0","endTime":"0","summary":"中金发表研究报告指，再鼎医药去年业绩稍微胜过该行预期，主要得益于艾加莫德(Efgartigimod)收入高企。公司为今年表现提供指引，收入达5.6亿美元至5.9亿美元，目标非通用会计准则经营盈利在今年第四季收支平衡，超该行预期。中金指，留意到公司在今明两年有大量的催化剂，料今年上半年会就ZL-1310公布更多数据，另预期会在上半年就Bemarituzumab递交内地上市申请。至于KarXT，该行料在明年开始商业化。该行上调再鼎医药H股目标价22.5%至34.41港元，维持“跑赢大市”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304144949989b1987&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304144949989b1987&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09688","ZLAB"],"gpt_icon":0},{"id":"1195942706","title":"异动解读 | 再鼎医药盘中大跌5.48%,分析师下调评级目标价或是主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1195942706","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195942706?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:38","pubTimestamp":1741012712,"startTime":"0","endTime":"0","summary":"再鼎医药(ZLAB)今日盘中大跌5.48%,引发市场广泛关注。公司在业务方面获得新利好,即其一款药品repotrectinib在台湾地区获批上市。但分析师下调对公司的评级和目标价或是导致股价下跌的主因。\n\n具体来说,美银美林证券下调了再鼎医药的评级,由之前的\"买入\"调整为\"中性\",同时下调了公司目标价格,由之前的29美元调整至36.10美元。这引发了市场对公司发展前景的担忧,令股价承压。\n\n对于分析师下调评级和目标价的具体原因,目前公司尚未作出回应。投资者期待公司能尽快解释清楚,并重申公司的发展方向和目标,以重拾市场信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 再鼎医药盘中大跌5.48%,分析师下调评级目标价或是主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.148},{"period":"1month","weight":-0.1153},{"period":"3month","weight":0.2557},{"period":"6month","weight":0.2052},{"period":"1year","weight":1.0563},{"period":"ytd","weight":0.2131}],"compareEarnings":[{"period":"1week","weight":-0.0907},{"period":"1month","weight":-0.1334},{"period":"3month","weight":-0.1464},{"period":"6month","weight":-0.1182},{"period":"1year","weight":-0.0152},{"period":"ytd","weight":-0.1379}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.10392},{"month":2,"riseRate":0.5,"avgChangeRate":0.014818},{"month":3,"riseRate":0.25,"avgChangeRate":-0.083122},{"month":4,"riseRate":0.375,"avgChangeRate":0.008403},{"month":5,"riseRate":0.571429,"avgChangeRate":0.03934},{"month":6,"riseRate":0.428571,"avgChangeRate":0.063316},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.00593},{"month":8,"riseRate":0.714286,"avgChangeRate":0.018507},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.066935},{"month":10,"riseRate":0.5,"avgChangeRate":-0.024776},{"month":11,"riseRate":0.625,"avgChangeRate":0.141461},{"month":12,"riseRate":0.5,"avgChangeRate":-0.016217}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}